Compare Intel Corp (INTC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Neurocrine Biosciences Inc — how do they compare? Intel Corp trades at $98.66 (market cap $491.89B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Intel Corp is far larger — about 29.3× Neurocrine Biosciences Inc's market cap, and Intel Corp pays a 2.24% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| INTC | NBIX | |
|---|---|---|
Market Cap | $491.89B | $16.76B |
Volume | 43,552,012 | — |
Sector | Technology | Health |
52-Week High | $140.94 | $185.50 |
52-Week Low | $21.81 | $123.10 |
Enterprise Value | $512.70B | $16.78B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $101.65, up 1.84% on the day, with a bullish technical signal from moving averages but a neutral oscillator stance. The company reported a net loss of $267 million in 2025 despite revenue of $52.85 billion, though it beat EPS estimates in recent quarters. Recent news highlights a $20 billion stock offering to fund AI expansion, causing short-term volatility but viewed as strategic for long-term growth.
Outlook is mixed: analyst consensus price target of $116.67 suggests upside, supported by AI investments, but high P/E of 904.17 and negative profit margins pose valuation risks. Key risks include intense competition, execution challenges in foundry growth, and reliance on capital raises amid cash burn in strategic segments.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
